Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase

Nutrients. 2017 Jun 12;9(6). pii: E596. doi: 10.3390/nu9060596. Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants. Made SMV1,2, Plat J3, Mensink RP4,5. Author information 1Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands. sanne.vandermade@maastrichtuniversity.nl.2Top Institute Food and Nutrition (TIFN), 6700 AN Wageningen, The Netherlands. sanne.vandermade@maastrichtuniversity.nl.3Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands. j.plat@maastrichtuniversity.nl.4Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands. r.mensink@maastrichtuniversity.nl.5Top Institute Food and Nutrition (TIFN), 6700 AN Wageningen, The Netherlands. r.mensink@maastrichtuniversity.nl. Abstract Studies on the effects of the long-term intake of trans-resveratrol on vascular function are conflicting. In addition, postprandial effects of long-term trans-resveratrol intake on endothelial function are not known. We therefore supplemented 45 overweight and slightly obese volunteers (25 men and 20 women) with a mean (±SD) age of 61 ± 7 years and body mass index of 28.3 ± 3.2 kg/m² in random order trans-resveratrol (2 × 75 mg/day) or placebo capsules for 4 weeks, separated by a washout period of at least 4 weeks. At the end of each intervention period, brachial artery flow-mediated vasodilation (FMD) was measured before and after meal consumption. Plasma biomarkers for endothelial function, inflammation, and glucose and lipid metabolism were also determined. Compared with the placebo, trans-resveratrol did not affect fasting FMD (2.9 ± 1.4% vs. 3.0 ± 1.9%; p = 0.69). After the postprandial test, changes in FMD (-0.7 ± 2.3% vs. 0.2 ± 2.6%; p = 0.13) were also not significantly different. Postprandial changes in biomarkers were also comparable. In conclusion, for overweight and slightly obese volunteers, a daily intake of 150 mg of trans-resveratrol for 4 weeks does not change plasma biomarkers of endothelial function or inflammation in the fasting state or postprandial phase. KEYWORDS:FLOW-MEDIATED VASODILATION; HUMANS; POSTPRANDIAL; TRANS-RESVERATROL; VASCULAR FUNCTION Endothelial Function Scientific Update Sponsored by Endothelix Inc. www.endothelix.com

Click here to view previous updates.